| Name | Title | Contact Details |
|---|
NeuWave Medical specializes in developing and commercializing energy-based minimally invasive medical devices. These devices must deliver improved healthcare economics and a better experience for patients in terms of outcomes or quality of life. NeuWave Medical, Inc. is a spin-off company from the University of Wisconsin - Madison. NeuWave arose as the result of an academic collaboration between engineers and physicians who wished to improve their ability to treat cancer and other important clinical problems. As a result, NeuWave is highly focused on solving real clinical problems in a manner that will directly benefit patients by being more effective, minimally invasive, and cost conscious.
Builders Benefits Inc is a Latham, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TrueCare is a healthcare provider that offers medical, dental, women’s health services, mental/behavioral health services, pharmacy and chiropractic care in San Diego and Riverside Counties.
CellASIC Corp. is a San Leandro, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic